The review proposal for this guidance is currently open for public consultation here.
Consultation on this document will open on 12 September 2016 at 9.00am and close on 10 October 2016 at 9.00am.
In July 2016 NICE commenced the review of this guidance, to register as a stakeholder please contact us at email@example.com.
NICE has developed medical technology guidance on Ambulight PDT.
NICE medical technologies guidance addresses specific technologies notified to NICE by manufacturers. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
Healthcare teams may want to use Ambulight PDT because it can be used to give photodynamic therapy in places other than hospitals, such as patients’ homes. It may also cause less pain than normal photodynamic therapy. However, NICE has said that the evidence does not show that Ambulight PDT would make services more efficient, and that there is not much evidence about how well it works. NICE has said that NHS organisations should take this into account, along with other features of Ambulight PDT, when deciding whether to use it.